TDMS Study 05110-01 Pathology Tables
INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)
NAPHTHALENE
NTP Experiment-Test: 05110-01 Report: PEIRPT05
Study Type: CHRONIC Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
Facility: Northrop Services, Inc.
Chemical CAS #: 91-20-3
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 75 75 75 75
Scheduled Sacrifice 5 7 6 6
Early Deaths
Dead 8 6 10 7
Moribund 2 1 6 10
Accident 1 1
Survivors
Terminal Sacrifice 59 56 51 50
Dead 1
Accident 1
Missing 3 1 2
Animals Examined Microscopically 69 65 68 67
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (65) (2) (60) (64)
Intestine Large, Cecum (66) (1) (60) (64)
Intestine Large, Colon (67) (2) (62) (66)
Intestine Large, Rectum (67) (3) (63) (63)
Intestine Small, Duodenum (66) (4) (61) (63)
Adenocarcinoma 1 (25%)
Intestine Small, Ileum (66) (1) (61) (63)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Intestine Small, Jejunum (65) (1) (61) (63)
Liver (68) (12) (67) (67)
Hepatocellular Carcinoma 1 (1%)
Hepatocellular Adenoma 2 (3%) 2 (17%) 2 (3%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Plasma Cell Tumor Malignant 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Sarcoma Stromal, Metastatic 1 (8%)
Mesentery (6) (3) (3)
Fat, Sarcoma, Metastatic, Uncertain Primary
Site 1 (33%)
Pancreas (69) (5) (65) (67)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Salivary Glands (68) (5) (64) (67)
Fibrosarcoma 1 (1%)
Stomach, Forestomach (67) (5) (67) (67)
Squamous Cell Carcinoma 1 (1%)
Squamous Cell Papilloma 2 (3%)
Stomach, Glandular (67) (5) (65) (67)
Page 2
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - cont
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (69) (4) (68) (67)
Fibrous Histiocytoma 1 (1%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland (66) (4) (67) (67)
Capsule, Adenoma 1 (2%)
Capsule, Sarcoma, Metastatic, Uncertain
Primary Site 1 (1%)
Adrenal Gland, Cortex (66) (4) (67) (67)
Osteosarcoma, Metastatic, Bone 1 (1%)
Adrenal Gland, Medulla (64) (4) (66) (66)
Osteosarcoma, Metastatic, Bone 1 (2%)
Pheochromocytoma Benign 1 (2%)
Islets, Pancreatic (69) (4) (66) (67)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Pituitary Gland (61) (4) (50) (54)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (69) (4) (67) (66)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Tissue NOS (1) (1) (2)
Osteosarcoma, Metastatic, Bone 1 (50%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (1)
Squamous Cell Carcinoma 1 (100%)
Ovary (69) (14) (66) (65)
Cystadenocarcinoma, Papillary 1 (1%) 1 (7%)
Cystadenoma, Papillary 2 (3%) 4 (6%)
Granulosa Cell Tumor Benign 1 (1%) 1 (2%)
Granulosa-Theca Tumor Benign 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (2%)
Sarcoma Stromal, Metastatic 1 (7%)
Teratoma Benign 1 (2%)
Endothelium, Sarcoma Stromal, Metastatic 1 (1%)
Page 3
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM - cont
Oviduct (2) (1) (4) (4)
Uterus (69) (41) (67) (66)
Sarcoma Stromal 1 (1%) 2 (5%)
Endometrium, Polyp Stromal 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (69) (4) (68) (67)
Hemangioma 1 (1%)
Hemangiosarcoma 1 (1%)
Osteosarcoma, Metastatic, Bone 1 (1%)
Lymph Node (69) (9) (67) (67)
Iliac, Sarcoma Stromal, Metastatic, Uterus 1 (1%)
Inguinal, Osteosarcoma, Metastatic, Bone 1 (1%)
Renal, Sarcoma Stromal, Metastatic, Uterus 1 (1%)
Lymph Node, Bronchial (46) (1) (46) (40)
Sarcoma, Metastatic, Uncertain Primary Site 1 (3%)
Lymph Node, Mandibular (66) (6) (62) (65)
Fibrosarcoma 1 (2%)
Lymph Node, Mediastinal (60) (6) (52) (57)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
Lymph Node, Mesenteric (67) (4) (60) (62)
Spleen (67) (13) (67) (67)
Hemangiosarcoma 3 (4%)
Plasma Cell Tumor Malignant 1 (1%)
Capsule, Sarcoma, Metastatic, Uncertain
Primary Site 1 (1%)
Thymus (64) (3) (60) (59)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (69) (5) (66) (66)
Adenocarcinoma 2 (3%) 1 (20%) 1 (2%) 2 (3%)
Skin (69) (6) (67) (67)
Squamous Cell Papilloma 1 (1%)
Subcutaneous Tissue, Fibroma 1 (1%)
Subcutaneous Tissue, Fibrosarcoma 1 (1%) 1 (17%) 2 (3%)
Subcutaneous Tissue, Sarcoma 1 (17%) 1 (1%)
____________________________________________________________________________________________________________________________________
Page 4
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (69) (4) (68) (67)
Femur, Osteosarcoma 1 (1%)
Humerus, Osteosarcoma 1 (1%)
Skeletal Muscle (3) (3)
Back, Osteosarcoma, Metastatic, Bone 1 (33%)
Hindlimb, Fibrosarcoma 1 (33%)
Hindlimb, Hemangiosarcoma 1 (33%)
Sternal, Osteosarcoma, Metastatic, Bone 1 (33%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (69) (4) (68) (67)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (68) (4) (64) (64)
Lung (69) (65) (68) (67)
Adenocarcinoma, Metastatic, Mammary Gland 1 (1%) 1 (1%)
Alveolar/Bronchiolar Adenoma 5 (7%) 1 (2%) 9 (13%) 12 (18%)
Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) 4 (6%) 3 (4%)
Alveolar/Bronchiolar Carcinoma 1 (1%)
Fibrosarcoma, Metastatic, Skin 1 (2%)
Osteosarcoma, Metastatic, Bone 1 (1%) 1 (1%)
Sarcoma, Metastatic, Skin 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Mediastinum, Sarcoma, Metastatic, Uncertain
Primary Site 1 (1%)
Nose (69) (65) (68) (67)
Adenoma 2 (3%)
Trachea (69) (4) (68) (66)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Ear (1)
Pinna, Fibrosarcoma 1 (100%)
Eye (2) (6) (2) (4)
Lids, Squamous Cell Papilloma 1 (25%)
Harderian Gland (1) (2) (1) (1)
Adenocarcinoma 2 (100%)
Adenoma 1 (100%)
____________________________________________________________________________________________________________________________________
Page 5
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (69) (7) (67) (67)
Plasma Cell Tumor Malignant 1 (1%)
Urinary Bladder (67) (1) (62) (63)
Sarcoma, Metastatic, Uncertain Primary Site 1 (2%)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(69) *(65) *(68) *(67)
Lymphoma Malignant Histiocytic 1 (1%) 2 (3%) 1 (1%) 3 (4%)
Lymphoma Malignant Lymphocytic 6 (9%) 5 (8%) 2 (3%) 2 (3%)
Lymphoma Malignant Mixed 1 (1%) 1 (2%) 4 (6%) 2 (3%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 6
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 23 22 28 35
Total Primary Neoplasms 28 25 33 48
Total Animals with Benign Neoplasms 15 7 19 22
Total Benign Neoplasms 15 7 19 24
Total Animals with Malignant Neoplasms 12 18 12 19
Total Malignant Neoplasms 13 18 14 24
Total Animals with Metastatic Neoplasms 1 2 3 4
Total Metastatic Neoplasm 3 3 10 19
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 7
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially in Study 75 75 75 75
Scheduled Sacrifice 5 5 6 7
Early Deaths
Moribund 13 7 3 5
Dead 31 10 2 5
Accident 2
Survivors
Dead 1 1
Terminal Sacrifice 26 50 59 58
Accident 1
Missing 1 2
Animals Examined Microscopically 70 69 67 68
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (57) (7) (61) (65)
Intestine Large, Cecum (56) (5) (65) (65)
Intestine Small, Duodenum (49) (5) (64) (66)
Adenocarcinoma 1 (2%) 1 (2%)
Liver (70) (33) (67) (68)
Hemangiosarcoma 1 (1%)
Hepatocellular Carcinoma 6 (9%) 4 (12%) 4 (6%) 3 (4%)
Hepatocellular Adenoma 3 (4%) 8 (24%) 3 (4%) 12 (18%)
Hepatocellular Adenoma, Multiple 2 (6%) 1 (1%)
Mesentery (1) (1)
Pancreas (67) (10) (66) (68)
Salivary Glands (69) (11) (67) (68)
Stomach, Forestomach (63) (10) (65) (68)
Stomach, Glandular (62) (10) (65) (68)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (70) (10) (67) (68)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Gland, Cortex (66) (9) (65) (68)
Adenoma 2 (3%)
Adrenal Gland, Medulla (66) (11) (64) (66)
Pheochromocytoma Benign 2 (3%) 1 (9%) 1 (2%)
Page 8
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - cont
Islets, Pancreatic (67) (9) (66) (68)
Pituitary Gland (52) (5) (58) (55)
Pars Distalis, Adenoma 1 (2%)
Thyroid Gland (67) (8) (66) (68)
Follicular Cell, Adenoma 1 (1%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (69) (11) (67) (68)
Penis (2) (2) (1)
Prostate (65) (11) (67) (66)
Testes (69) (12) (67) (68)
Fibrosarcoma, Metastatic, Skin 1 (8%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (70) (10) (67) (68)
Lymph Node (67) (14) (67) (68)
Lymph Node, Bronchial (38) (5) (57) (43)
Lymph Node, Mandibular (61) (8) (59) (66)
Lymph Node, Mediastinal (37) (4) (43) (47)
Lymph Node, Mesenteric (57) (4) (66) (63)
Spleen (69) (18) (67) (68)
Thymus (47) (1) (63) (63)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (69) (21) (67) (68)
Subcutaneous Tissue, Fibroma 3 (4%) 3 (14%) 1 (1%)
Subcutaneous Tissue, Fibroma, Multiple 1 (1%)
Subcutaneous Tissue, Fibrosarcoma 11 (16%) 6 (29%) 4 (6%)
Subcutaneous Tissue, Fibrous Histiocytoma 1 (1%) 1 (1%)
Subcutaneous Tissue, Neurofibrosarcoma 2 (3%) 1 (1%)
Subcutaneous Tissue, Sarcoma 6 (9%) 2 (10%) 2 (3%)
Subcutaneous Tissue, Sarcoma, Multiple 1 (1%)
____________________________________________________________________________________________________________________________________
Page 9
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (4)
Sarcoma, Metastatic, Skin 1 (25%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (70) (10) (67) (68)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (70) (69) (67) (68)
Alveolar/Bronchiolar Adenoma 7 (10%) 13 (19%) 12 (18%) 7 (10%)
Alveolar/Bronchiolar Adenoma, Multiple 2 (3%) 3 (4%) 5 (7%)
Alveolar/Bronchiolar Carcinoma 3 (4%) 4 (6%) 3 (4%)
Fibrosarcoma, Metastatic 1 (1%)
Fibrosarcoma, Metastatic, Skin 1 (1%)
Hepatocellular Carcinoma, Metastatic, Liver 3 (4%)
Sarcoma, Metastatic, Skin 1 (1%) 1 (1%)
Sarcoma, Metastatic, Uncertain Primary Site 1 (1%)
Nose (70) (69) (67) (68)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Harderian Gland (1) (1) (1) (1)
Adenoma 1 (100%) 1 (100%) 1 (100%) 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (70) (16) (67) (68)
Adenoma 1 (1%)
Carcinoma 1 (1%)
Urinary Bladder (60) (16) (66) (68)
____________________________________________________________________________________________________________________________________
SYSTEMIC LESIONS
Multiple Organs *(70) *(69) *(67) *(68)
Leukemia Granulocytic 1 (1%)
Lymphoma Malignant Histiocytic 1 (1%) 1 (1%)
Lymphoma Malignant Lymphocytic 3 (4%) 2 (3%) 3 (4%) 1 (1%)
____________________________________________________________________________________________________________________________________
* Number of animals with any tissue examined microscopically
Page 10
NTP Experiment-Test: 05110-01 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05
Study Type: CHRONIC NAPHTHALENE Date: 09/14/94
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:12:05
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 PPM 30 PPM 30 PPM
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY
Total Animals with Primary Neoplasms (b) 36 36 27 39
Total Primary Neoplasms 49 48 34 48
Total Animals with Benign Neoplasms 15 24 19 25
Total Benign Neoplasms 19 30 22 28
Total Animals with Malignant Neoplasms 26 16 12 19
Total Malignant Neoplasms 30 18 12 20
Total Animals with Metastatic Neoplasms 4 3 1
Total Metastatic Neoplasm 4 5 1
Total Animals with Malignant Neoplasms 1
Uncertain Primary Site
Total Animals with Neoplasms Uncertain-
Benign or Malignant
Total Uncertain Neoplasms
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
b Primary tumors: all tumors except metastatic tumors
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------